Skip to main content
Fig. 10 | World Journal of Surgical Oncology

Fig. 10

From: Identification and validation of an immune-associated RNA-binding proteins signature to predict clinical outcomes and therapeutic responses in colon cancer patients

Fig. 10

Drug sensitivity analysis of two RBPs (FBXO17 and PPARGC1A). FBXO17 expression was negatively associated with b Palbociclib, c PX-31, j Perifosine, k LDK-378, m Entinostat drug sensitivity, and positively related to e Bleomycin, g Gemcitabine, h Irofulven, o Sonidegib, and p Lenvatinib drug sensitivity. PPARGC1A expression was negatively related to d Triciribine phosphate, f 7-Hydroxystaurosporine, and l Dasatinib drug sensitivity, and positively related to a Dabrafenib, i Vemurafenib, and n Hydrastinine HCl drug sensitivity. X-axis is gene expression; Y-axis is IC50 of each drug

Back to article page